The CLIA Molecular Diagnostics Laboratory (CMDL) provides an array of services for groups at the NIH Clinical Center, Fort Detrick, and Hood College, among others. They support cancer- and disease-related research by making polymerase chain reaction (PCR)-based genetic mutation detection, DNA sequencing, and gene expression technologies available to researchers and by examining human specimens to provide health assessment, prevention, diagnosis, and disease treatment information to interested parties.
*RESEARCH ASSAY TO CLIA DEVELOPMENT AND VALIDATION*
Contact our lab at NCI-FrederickCMDLCLIAGroup@mail.nih.gov, via Stephen Hewitt (CLIA Director) (301-273-5257) or via Kristen Pike (301-846-6897).
For a current list of publications and additional information please visit our Website: https://frederick.cancer.gov/science/laboratories/moleculardiagnosticslab
CLIA-Certified Technologies Offered:
- Fragment Analysis for Micro-satellite Instability Detection
- PharmacoScan Array for Pharmacogenomics
- Mutation Detection for PCR and Sanger Sequencing
- DNA Extraction from Blood and Saliva
Additional Capabilities Include:
- Droplet Digital PCR (ddPCR)
- Quantitative PCR (qPCR)
- Mass Spectrometry
- Next-Generation Sequencing (NGS)
- Automated Staining (RNAscope)
- Single Molecule Counting (NanoString nCounter)
- GeneChip Array Plate assays for Gene Titan
- Illumina MiSeqDx for Next-Generation Sequencing (NGS)
- Leica BondRx Stainer for RNAScope assays
- Thermo Fisher QuantStudio for qPCR
- Illumina NextSeq for Next-Generation Sequencing (NGS)
- BioRad QX200 for Droplet Digital PCR (ddPCR)
- Beckman FXp robotic liquid handler for automation
- Microm Microtome for sectioning formalin fixed paraffin embedded (FFPE) tissues.